Search
01/09/2024
Real-world effectiveness of switching to Benralizumab in patients with severe asthma in the Catalan population. Catalan Society of Pulmonology (SOCAP) Registry
Arismendi, E, Muñoz, M, Crespo, A, Ausin, P, Castillo, JA, Curto, E, Lapuente, A, Arguedas, AM, Martínez-Rivera, C, Monserrate, D, Muñoz, X, Ojanguren, I, Palones, E, Paredes, M, Pilia, F, Picado, C, Sabater, G, Sabadell, C, Sogo, A, Cañete, C. Real-world effectiveness of switching to Benralizumab in patients with severe asthma in the Catalan population. Catalan Society of Pulmonology (SOCAP) Registry. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA3926. PMID:. IF:21.000(Q1/1D).
01/09/2024
Molecular insights into hypoxic burden physiopathology in OSA: a proteomic perspective
Pinilla, L, Dodani, K, Benitez, I, Esmaeli, N, Gracia-Lavedán, E, Torres, G, Minguez, O, Martinez, D, Martínez-García, MA, Abad, J, Masdeu, MJ, Mediano, O, Muñoz, C, Cabriada, V, Duran-Cantolla, J, Mayos, M, Coloma, R, Montserrat, JM, De la Peña, M, Cano-Pumarega, I, Barbé, F, Azarbarzin, A, Sanchez-De-la-Torre, M. Molecular insights into hypoxic burden physiopathology in OSA: a proteomic perspective. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA2693. PMID:. IF:21.000(Q1/1D).
01/09/2024
Improvement in lung function after six months of treatment with extrafine formulation single-inhaler triple therapy (efSITT) in patients with asthma-TriMaximize Study
Gessner, C, Bogoevska, V, Nachtigall, D, Russell, R, Ulrik, CS, Pohl, W, Plaza, V, Bourdin, A, Criée, CP, Trinkmann, F. Improvement in lung function after six months of treatment with extrafine formulation single-inhaler triple therapy (efSITT) in patients with asthma-TriMaximize Study. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA2121. PMID:. IF:21.000(Q1/1D).
01/09/2024
Impact of extrafine formulation single-inhaler triple therapy on asthma control and treatment adherence after six months of treatment in patients with asthma-TriMaximize study
Greulich, T, Bogoevska, V, Nachtigall, D, Russell, R, Suppli, C, Wolfgang, U, Pohl, W, Plaza, V, Bourdin, A, Baumeister, S, Gessner, C. Impact of extrafine formulation single-inhaler triple therapy on asthma control and treatment adherence after six months of treatment in patients with asthma-TriMaximize study. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA3907. PMID:. IF:21.000(Q1/1D).
01/09/2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
Rodriguez-Vida, A, Valderrama, BP, Castellano, D, Pinto, A, Mellado, B, Puente, J, Climent, MA, Domenech, M, Vazquez, F, Perez-Gracia, JL, Bonfill, T, Morales-Barrera, R, Gonzalez-Billalabeitia, E, Garcia-del-Muro, X, Maroto, P, Navarro-Gorro, N, Juanpere, N, Juan, O, Bellmunt, J. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9)DOI:10.1016/j.esmoop.2024.103690. PMID:39214051. IF:8.300(Q1/2D).
01/09/2024
ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer
Barba, A, López-Vilaró, L, Ferre, M, Majem, M, Martinez-Recio, S, Bell, O, Arranz, MJ, Salazar, J, Sullivan, I. ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer. Pharmaceutics. 2024; 16(9)DOI:10.3390/pharmaceutics16091121. PMID:39339159. IF:5.500(Q1/1D).